Trial Profile
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- 12 Jan 2024 Status changed from recruiting to discontinued.
- 30 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Jul 2024.
- 30 Jun 2022 Planned primary completion date changed from 1 May 2022 to 1 Jul 2024.